Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in refractory adult-onset Still’s disease
ChiCTR2500108227Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sirolimus in adult-onset Still's disease (AOSD), sponsored by Ruijin Hospital. Primary endpoint: AOSD Disease Activity Score at week 12. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on ChiCTR2500108227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108227.